Alder BioPharmaceuticals Announces Closing of $250M of 2.50% Convertible Senior Notes Due 2025 Post author:Sam Post published:February 1, 2018 Post category:BioPharma Alder intends to use the cash to fund the development and commercialization of eptinezumab. Source: BioSpace You Might Also Like Troubling Times for Shire as Execs Jump Ship and Employee Satisfaction is at an All Time Low August 30, 2017 For A German Medical Device Startup the Road to Being Acquired Went Through Houston April 12, 2017 Merck Chemist Arrested for Stealing Deadly Chemical February 13, 2018
Troubling Times for Shire as Execs Jump Ship and Employee Satisfaction is at an All Time Low August 30, 2017